We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana Eyes 3% Medicare Advantage Margin: Can It Deliver?
Read MoreHide Full Article
Key Takeaways
Humana aims for a 3% Medicare Advantage margin by 2028 as it rebuilds long-term profitability.
HUM expects about 25% individual Medicare Advantage membership growth in 2026 through disciplined execution.
Humana reaffirmed at least $9.00 adjusted EPS guidance for 2026 despite Star Ratings headwinds.
Humana Inc.’s (HUM - Free Report) turnaround is no longer about growing membership, it's about rebuilding profitability. The company has set a goal of achieving a 3% Medicare Advantage margin by 2028, making it one of the most important milestones for its long-term earnings recovery. The key question is whether Humana can translate that strategy into sustainable profit growth.
Unlike many managed care companies that have scaled back benefits to protect margins, Humana continues to expect approximately 25% growth in individual Medicare Advantage membership in 2026. The focus is on attracting higher-quality members through disciplined pricing, stronger product design and better retention rather than pursuing growth at any cost.
Humana is working to improve medical cost trends through tighter care management and stronger operational execution. It is also investing to rebuild its Medicare Star Ratings, a key driver of future reimbursement and profitability. Higher Star Ratings would increase quality bonus payments, strengthen its competitive position and support long-term profitability.
Despite elevated healthcare utilization and a challenging regulatory environment, Humana reaffirmed its 2026 adjusted EPS guidance of at least $9.00, reflecting confidence in its turnaround plan despite the temporary Star Ratings headwind. The near-term focus is on controlling medical costs, improving Star Ratings and turning membership growth into higher profits. Delivering on these priorities will be key to reaching the 3% Medicare Advantage margin target and supporting a sustained earnings recovery.
How Are Humana's Peers Positioned?
Restoring Medicare Advantage profitability has become a key priority across the health insurance industry. UnitedHealth Group Incorporated (UNH - Free Report) and CVS Health Corporation (CVS - Free Report) are also focused on improving margins through disciplined execution.
UnitedHealth Group is emphasizing disciplined pricing, stronger care management and value-based care to improve Medicare Advantage margins. UNH is prioritizing sustainable profitability over aggressive growth, much like Humana.
CVS Health is repricing Medicare Advantage plans, refining benefits and strengthening medical cost management to improve profitability. CVS is taking a disciplined approach to rebuild margins and support long-term earnings growth.
HUM’s Price Performance, Valuation and Estimates
Shares of HUM have gained 53.1% year to date, outperforming the broader industry’s 28.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, HUM trades at a forward price-to-earnings ratio of 32.21X, up from the industry average of 18.48X. Humana carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HUM’s 2026 earnings implies a 47.4% deterioration year over year, followed by a 66.1% improvement next year.
View the Zacks #1 Rank List
Image: Bigstock
Humana Eyes 3% Medicare Advantage Margin: Can It Deliver?
Key Takeaways
Humana Inc.’s (HUM - Free Report) turnaround is no longer about growing membership, it's about rebuilding profitability. The company has set a goal of achieving a 3% Medicare Advantage margin by 2028, making it one of the most important milestones for its long-term earnings recovery. The key question is whether Humana can translate that strategy into sustainable profit growth.
Unlike many managed care companies that have scaled back benefits to protect margins, Humana continues to expect approximately 25% growth in individual Medicare Advantage membership in 2026. The focus is on attracting higher-quality members through disciplined pricing, stronger product design and better retention rather than pursuing growth at any cost.
Humana is working to improve medical cost trends through tighter care management and stronger operational execution. It is also investing to rebuild its Medicare Star Ratings, a key driver of future reimbursement and profitability. Higher Star Ratings would increase quality bonus payments, strengthen its competitive position and support long-term profitability.
Despite elevated healthcare utilization and a challenging regulatory environment, Humana reaffirmed its 2026 adjusted EPS guidance of at least $9.00, reflecting confidence in its turnaround plan despite the temporary Star Ratings headwind. The near-term focus is on controlling medical costs, improving Star Ratings and turning membership growth into higher profits. Delivering on these priorities will be key to reaching the 3% Medicare Advantage margin target and supporting a sustained earnings recovery.
How Are Humana's Peers Positioned?
Restoring Medicare Advantage profitability has become a key priority across the health insurance industry. UnitedHealth Group Incorporated (UNH - Free Report) and CVS Health Corporation (CVS - Free Report) are also focused on improving margins through disciplined execution.
UnitedHealth Group is emphasizing disciplined pricing, stronger care management and value-based care to improve Medicare Advantage margins. UNH is prioritizing sustainable profitability over aggressive growth, much like Humana.
CVS Health is repricing Medicare Advantage plans, refining benefits and strengthening medical cost management to improve profitability. CVS is taking a disciplined approach to rebuild margins and support long-term earnings growth.
HUM’s Price Performance, Valuation and Estimates
Shares of HUM have gained 53.1% year to date, outperforming the broader industry’s 28.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, HUM trades at a forward price-to-earnings ratio of 32.21X, up from the industry average of 18.48X. Humana carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HUM’s 2026 earnings implies a 47.4% deterioration year over year, followed by a 66.1% improvement next year.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.